What are FDA’s expectations for establishing acceptable intakes (Als) for potential cohort of concern (CoC) nitrosamines with insufficient safety data?

Limits of Nitrosamines
1

This and more questions related to Safety on this document recently published by FDA from a recent FDA-Industry meeting AAM/CHPA/PhRMA May 4th

QA Written Responses_Joint Industry Group Meeting on Nitrosamines_final.pdf (133.3 KB)

1 Like